Signaturefd LLC Lowers Stake in Royalty Pharma plc (NASDAQ:RPRX)

Signaturefd LLC reduced its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX) by 32.3% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 3,854 shares of the biopharmaceutical company’s stock after selling 1,840 shares during the period. Signaturefd LLC’s holdings in Royalty Pharma were worth $109,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of RPRX. Versant Capital Management Inc grew its position in Royalty Pharma by 5,215.0% during the 2nd quarter. Versant Capital Management Inc now owns 1,063 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 1,043 shares during the last quarter. Gladius Capital Management LP purchased a new position in Royalty Pharma during the 2nd quarter worth $32,000. Blue Trust Inc. grew its position in Royalty Pharma by 362.7% during the 3rd quarter. Blue Trust Inc. now owns 1,203 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 943 shares during the last quarter. Fidelis Capital Partners LLC purchased a new position in Royalty Pharma during the 1st quarter worth $46,000. Finally, EverSource Wealth Advisors LLC grew its position in Royalty Pharma by 32.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 655 shares during the last quarter. 54.35% of the stock is owned by hedge funds and other institutional investors.

Royalty Pharma Stock Up 1.2 %

Shares of NASDAQ RPRX opened at $27.26 on Tuesday. The company has a quick ratio of 9.35, a current ratio of 9.35 and a debt-to-equity ratio of 0.78. Royalty Pharma plc has a 52 week low of $25.20 and a 52 week high of $31.66. The firm has a 50-day moving average price of $28.02 and a 200 day moving average price of $27.59. The stock has a market capitalization of $16.18 billion, a price-to-earnings ratio of 24.12, a price-to-earnings-growth ratio of 3.97 and a beta of 0.46.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $0.96 EPS for the quarter, beating the consensus estimate of $0.95 by $0.01. Royalty Pharma had a net margin of 30.08% and a return on equity of 23.61%. The firm had revenue of $537.00 million during the quarter, compared to analysts’ expectations of $600.83 million. During the same quarter last year, the business earned $0.85 earnings per share. Equities research analysts anticipate that Royalty Pharma plc will post 4.05 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be paid a $0.21 dividend. This represents a $0.84 annualized dividend and a dividend yield of 3.08%. The ex-dividend date is Friday, November 15th. Royalty Pharma’s dividend payout ratio (DPR) is 74.34%.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Citigroup lowered their price objective on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a research report on Friday. The Goldman Sachs Group raised their target price on shares of Royalty Pharma from $50.00 to $51.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. Morgan Stanley raised their target price on shares of Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a research note on Thursday, July 11th. Finally, StockNews.com cut shares of Royalty Pharma from a “buy” rating to a “hold” rating in a research note on Monday. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $41.67.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.